Analytical Data
-
Gene name
CDC19
- Application
-
Alternative Names
cell division cycle protein 19
-
Species
Saccharomyces cerevisiae
-
Source
Yeast
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P00549
-
Expression Region
2-500aa
-
Molecular Weight
56.4 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CDC19, also known as cyclin-dependent kinase 19, is a crucial protein in the regulation of the cell cycle, particularly in the transition between different phases of cell division. It belongs to the family of cyclin-dependent kinases (CDKs) that play essential roles in controlling cellular proliferation and ensuring proper cell cycle progression. The study of CDC19 recombinant protein has gained attention due to its significant implications in cancer research, where dysregulation of CDK activity often leads to uncontrolled cell growth. Researchers have focused on characterizing CDC19's structure, function, and interaction with various cyclins and other regulatory proteins. Understanding the mechanisms by which CDC19 operates can provide insights into its role in normal cell cycle regulation and how its aberrations contribute to oncogenesis. Moreover, the development of CDC19 inhibitors has emerged as a promising therapeutic strategy for treating specific cancers. By producing CDC19 as a recombinant protein, scientists can explore its biochemical properties, evaluate potential inhibitors, and assess the protein's functionality in vitro, paving the way for novel cancer therapies. Through these studies, CDC19 is positioned as an important target for drug discovery and a vital component in the ongoing efforts to develop effective cancer treatment strategies.
